Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01946633
Other study ID # GNF-NaviCam-001
Secondary ID
Status Recruiting
Phase N/A
First received September 12, 2013
Last updated October 28, 2013
Start date October 2013

Study information

Verified date October 2013
Source Nanfang Hospital of Southern Medical University
Contact xinying Wang, Associate Professor
Phone 86-020-61541540
Email sunwingwxy@163.com
Is FDA regulated No
Health authority China:Institutional Review Board of Nanfang Hospital, Southern Medical University
Study type Interventional

Clinical Trial Summary

The present study is a feasibility study to assess the safety and efficacy of wireless capsule endoscope and compare the data obtained with those obtained by using a conventional esophagogastroduodenoscopy.

The product was developed and manufacture in China.(the NaviCam. AKC-1.China)


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- upper abdominal symptoms (=1 year )

- surveillance gastroscopy for known gastric ulcer or polyps

- history of gastric ulcer or polyps (=1w)at Nanfang Hospital were enrolled.

Exclusion Criteria:

- dysphagia

- suspected or documented digestive tract malformation ,obstruction, strictures or fistula

- acute upper GI bleeding, acute enteritis, acute ischemia disease

- history of abdominal operations

- impaired renal function, congestive heart failure

- patients with critical condition or mental illness

- patients with, known allergy to polymer material or antifoam agent

- patients with cardiac pacemakers or other implanted electromedical devices,magnetic resonance imaging ( mri) examination in 7 days

- pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
magnetic-controlled capsule endoscopy(Navicam)


Locations

Country Name City State
China Departement of Gastroenterology, Nanfang Hospital, Southern Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Nanfang Hospital of Southern Medical University

Country where clinical trial is conducted

China, 

References & Publications (1)

Keller J, Fibbe C, Volke F, Gerber J, Mosse AC, Reimann-Zawadzki M, Rabinovitz E, Layer P, Schmitt D, Andresen V, Rosien U, Swain P. Inspection of the human stomach using remote-controlled capsule endoscopy: a feasibility study in healthy volunteers (with videos). Gastrointest Endosc. 2011 Jan;73(1):22-8. doi: 10.1016/j.gie.2010.08.053. Epub 2010 Nov 9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary the percentage of complete visualization of anatomic landmarks the percentage of patients in whom there was complete visualization of the gastric surface in the antrum, body, and fundus and identification of the cardia and pylorus 2 year No
Primary examination time and the percentage of abnormal finding examination time and the percentage of abnormal findings seen on gastroscopy that were reproducible by capsule endoscopy 2 year No
Secondary adverse effect any discomfort like chest pain, nausea will be documented. capsule retention(defined as not extrusion in 14 days)will be documented. 2 year Yes
Secondary Acceptability Acceptability to patients was assessed by means of a questionnaire, with ratings on a scale of 0 to 10 and examination chosen for next time. completed in the recovery room immediately after capsule examination. 2 year Yes
See also
  Status Clinical Trial Phase
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Completed NCT03291418 - To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects Phase 1/Phase 2
Not yet recruiting NCT05526339 - HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients N/A
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Terminated NCT00594854 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec Phase 3
Completed NCT01129011 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Phase 3
Completed NCT00527787 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Phase 3
Recruiting NCT05517408 - Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients. N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Completed NCT01150162 - Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation Phase 3
Recruiting NCT01037491 - Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets N/A
Completed NCT00960869 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Phase 3
Completed NCT00961350 - A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Phase 3
Completed NCT00595517 - Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer Phase 3
Completed NCT00428701 - An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium Phase 4
Completed NCT01452711 - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer Phase 3
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Completed NCT02761512 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer Phase 3
Recruiting NCT03057171 - A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA
Completed NCT01568398 - A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Phase 3